2021 Fiscal Year Final Research Report

Preventive medicine through inflammation cellular sociology

Administrative Group

PDF

Project Area	Preventive medicine through inflammation cellular sociology
Project/Area Number	17H06391
Research Category	Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area)
Allocation Type	Single-year Grants
Review Section	Complex systems
Research Institution	Tokyo University of Science (2018-2021) The University of Tokyo (2017)
Principal Investigator	Matsushima Kouji 東京理科大学, 研究推進機構生命医科学研究所, 教授 (50222427)
Co-Investigator(Kenkyū-buntansha)	橋本真一和歌山県立医科大学, 先端医学研究所, 教授 (00313099) 藤渕航京都大学, iPS細胞研究所, 教授 (60273512)
Project Period (FY)	2017-06-30 – 2022-03-31
Keywords	免疫 / 遺伝子 / 情報工学 / モデル化 / 病理学
Outline of Final Research Achievements	The Center for the analysis of Cellular Society of Inflammation, which supports scRNA-seq, various omics analyses, and information analysis, was set up under the General Affairs Group to support each planned and publicly research project. By using the standardized and optimized cell preparation technology of the project leaders and the highly sensitive and accurate scRNA-seq technology developed originally by the project leaders as the common basic technology for the project, a disease scRNA-seq database was constructed to enable cross-sectional data comparison across diseases and organs. We have also established a novel information analysis technology for biological interpretation of these data. Various target cells and molecules that could lead to the prevention and treatment of individual diseases have been obtained, and are expected to be applied to clinical development and disease prevention and treatment in the future.
Free Research Field	複合領域
Academic Significance and Societal Importance of the Research Achievements	肺、肝臓、腎臓、膵臓、腸管、皮膚などの疾患モデル、臨床検体について、サンプル調製からデータ解析までの工程を標準化したscRNA-seqデータを横断的に集積した炎症細胞社会データベースは、今後の疾患研究と創薬、そして予防戦略の構築に大きく貢献すると期待している。また、肺線維症における、病的C1q+ マクロファージやアミノ酸トランスポーター関連分子とその制御による線維化予防、2型糖尿病の未病状態特異的マーカーの同定、肝線維化診断マーカーの同定、慢性腎障害の予防剤、老化細胞除去剤、脳障害に対する保護剤などが見いだされており、今後の臨床開発への進展、疾患予防・治療への応用が期待される。